INS and metabolic disease: To get information potentially useful for the development of pharmacological strategies against cognitive decline in metabolic disease, we tested the effects of the non-specific inhibitor of S-palmitoylation, 2-BP, on synaptic plasticity and cognitive impairment in our models of brain insulin resistance.